Physician

Hitesh Patel, M.D.

According to 2025 Medicare claims, Hitesh Patel, M.D. (NPI: 1831191246) practices medical oncology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33756-3314.

Patel's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 645 traditional Medicare patients, billed 274,479 HCPCS/CPT codes, and received $3,309,733 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 789 prescription claims across 148 beneficiaries totaling $2,495,939 in drug costs, led by Cabometyx (Cabozantinib S-Malate). 2020 DME data shows 11 claims. Open Payments data shows 122 records totaling $4,138. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $1,339,456 to $2,495,939. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	923	322,354	$3,195,172
2016	940	347,141	$3,650,973
2017	968	351,189	$3,962,425
2018	931	305,779	$3,611,471
2019	1,083	302,803	$3,790,069
2020	949	301,550	$3,484,803
2021	827	353,169	$4,777,118
2022	731	299,731	$3,621,534
2023	745	322,622	$3,828,509
2024	645	274,479	$3,309,733

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	221	1,251	$1,339,456
2016	209	1,003	$1,223,634
2017	198	990	$1,549,503
2018	185	1,018	$1,788,561
2019	169	752	$1,847,768
2020	150	729	$2,021,785
2021	149	784	$2,757,041
2022	132	646	$2,719,525
2023	131	705	$1,991,088
2024	148	789	$2,495,939

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	119	$19,793
2016	N/R	110	$4,656
2017	N/R	N/R	N/R
2018	N/R	42	$9,397
2019	N/R	24	$3,950
2020	N/R	11	$1,095
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	252	804	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	331	582	$65
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	185	280	$13
36415	Insertion of needle into vein for collection of blood sample	453	1,409	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	475	1,952	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Cabometyx	Cabozantinib S-Malate	16	480	$407,246
Revlimid	Lenalidomide	23	644	$405,727
Jakafi	Ruxolitinib Phosphate	13	390	$214,520
Xtandi	Enzalutamide	14	420	$201,549
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	11	308	$65,600

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	122	$4,138	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Hitesh Patel, M.D.?

Tedicare shows public-source Medicare data for Hitesh Patel, M.D. (NPI 1831191246), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Hitesh Patel, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Hitesh Patel, M.D.?

Hitesh Patel, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Hitesh Patel, M.D. have Open Payments data?

Hitesh Patel, M.D. has 122 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.